TY - JOUR
T1 - How do transurethral needle ablation of the prostate and transurethral microwave thermotherapy compare with transurethral prostatectomy?
AU - Gonzalez, Ricardo R.
AU - Te, Alexis E.
N1 - Publisher Copyright:
© 2003, Current Science Inc.
PY - 2003/7
Y1 - 2003/7
N2 - Throughout the past decade, several minimally invasive therapies for benign prostatic hyperplasia (BPH) have emerged to challenge transurethral prostatectomy (TURP) in efficacy and safety. This review compares high- and lowenergy transurethral microwave thermotherapy (TUMT) and transurethral needle ablation (TUNA) of the prostate with TURP in clinical efficacy and safety. In reducing benign prostatic hyperplasia (BPH) symptoms, TUNA and TUMT are, at best, equal to TURP. However, the effects of TUMT and TUNA on objective measures of obstructive uropathy are minimal and less durable compared with TURP. The sole determinant of when and how to treat a patient with BPH is not solely a therapy’s clinical effectiveness. Other multiple factors must be considered, including safety, adverse effects, sexual function, and cost. The role of TUNA and TUMT lies in offering a cost-effective alternative for achieving substantial improvement in quality of life at an acceptable risk level for treatment-associated complications.
AB - Throughout the past decade, several minimally invasive therapies for benign prostatic hyperplasia (BPH) have emerged to challenge transurethral prostatectomy (TURP) in efficacy and safety. This review compares high- and lowenergy transurethral microwave thermotherapy (TUMT) and transurethral needle ablation (TUNA) of the prostate with TURP in clinical efficacy and safety. In reducing benign prostatic hyperplasia (BPH) symptoms, TUNA and TUMT are, at best, equal to TURP. However, the effects of TUMT and TUNA on objective measures of obstructive uropathy are minimal and less durable compared with TURP. The sole determinant of when and how to treat a patient with BPH is not solely a therapy’s clinical effectiveness. Other multiple factors must be considered, including safety, adverse effects, sexual function, and cost. The role of TUNA and TUMT lies in offering a cost-effective alternative for achieving substantial improvement in quality of life at an acceptable risk level for treatment-associated complications.
KW - Benign Prostatic Hyperplasia
KW - International Prostate Symptom Score
KW - International Prostate Symptom Score Score
KW - Maximum Flow Rate
KW - Transurethral Prostatectomy
UR - http://www.scopus.com/inward/record.url?scp=0142166246&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0142166246&partnerID=8YFLogxK
U2 - 10.1007/s11934-003-0088-x
DO - 10.1007/s11934-003-0088-x
M3 - Article
C2 - 12882722
AN - SCOPUS:0142166246
SN - 1527-2737
VL - 4
SP - 297
EP - 306
JO - Current Urology Reports
JF - Current Urology Reports
IS - 4
ER -